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Angiogenesis, the fundamental process by which new blood vessels form from existing ones, depends on precise
spatial and temporal gene expression within specific compartments of the endothelium. However, the molecular
links between proangiogenic signals and downstream gene expression remain unclear. During sprouting angiogen-
esis, the specification of endothelial cells into the tip cells that lead new blood vessel sprouts is coordinated by
vascular endothelial growth factor A (VEGFA) andDelta-like ligand 4 (Dll4)/Notch signaling and requires high levels
of Notch ligand DLL4. Here, we identify MEF2 transcription factors as crucial regulators of sprouting angiogenesis
directly downstream from VEGFA. Through the characterization of a Dll4 enhancer directing expression to endo-
thelial cells at the angiogenic front, we found that MEF2 factors directly transcriptionally activate the expression of
Dll4 and many other key genes up-regulated during sprouting angiogenesis in both physiological and tumor vas-
cularization. Unlike ETS-mediated regulation, MEF2-binding motifs are not ubiquitous to all endothelial gene en-
hancers and promoters but are instead overrepresented around genes associated with sprouting angiogenesis. MEF2
target gene activation is directly linked to VEGFA-induced release of repressive histone deacetylases and concurrent
recruitment of the histone acetyltransferase EP300 to MEF2 target gene regulatory elements, thus establishing
MEF2 factors as the transcriptional effectors of VEGFA signaling during angiogenesis.
[Keywords: sprouting angiogenesis; MEF2 transcription factors; HLX regulation; Dll4 regulation]
Supplemental material is available for this article.
Received December 10, 2015; revised version accepted September 29, 2016.
Sprouting angiogenesis, in which new blood vessels form
from existing ones, is driven in response to insufficient
supplies of nutrients and oxygen. This response involves
an exquisitely regulated pattern of gene expression
directly downstream from vascular endothelial growth
factor A (VEGFA) stimulation (Hellström et al. 2007; Ben-
edito et al. 2009). As a consequence of these stimuli, a sub-
set of endothelial cells known as tip cells forms polarized
filopodia protrusions and assumes the lead positions at
the tip of each blood vessel sprout (Gerhardt et al. 2003).
Neighboring angiogenic endothelial cells with greater
proliferative activity, known as stalk cells, contribute to
elongation, stability, and lumenization of the new sprout,
while other endothelial cells maintain a quiescent state,
thus ensuring the stability of the existing vasculature
(Gerhardt et al. 2003).
While many factors can elicit an angiogenic response,
and numerous pathways influence sprouting angiogene-
sis, the Notch signaling pathway is crucially required to
coordinate endothelial cell behavior during vessel pat-
terning downstream from VEGFA signaling. In particular,
the specification of endothelial cells into tip and stalk
cells is regulated by Delta-like ligand 4 (Dll4)/Notch8Present address: School of Life Sciences, University of Hull, Kingston-
upon-Hull HU6 7RX, United Kingdom
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signaling (Hellström et al. 2007). Higher levels of the
Notch ligand DLL4 in tip cells results in increased Notch
signaling in the neighboring stalk cell, which in turn ac-
tively suppresses the tip cell phenotype (Hellström et al.
2007; Jakobsson et al. 2010).
The mRNA expression patterns of many vascular
genes, including Dll4, are precisely controlled at the an-
giogenic front (Claxton and Fruttiger 2004; del Toro
et al. 2010; Strasser et al. 2010), supporting a role for tran-
scriptional regulation in this process. However, the tran-
scriptional networks that elicit this specific response to
VEGFA gradients are very poorly understood. While a
number of transcription factors influence angiogenesis
(De Val and Black 2009), gene ablation studies often result
in similar vascular phenotypes, making it challenging to
ascribe specific roles to different transcription factors.
Some implicated transcription factors, such as members
of the ETS factor family, including ERG (Randi et al.
2009; Birdsey et al. 2015), play a role in the regulation of
most endothelial-expressed genes (De Val and Black
2009), including those not expressed at the angiogenic
front (e.g., Tie2), suggesting that they are unable to pro-
vide the required specificity individually. Furthermore,
the lack of any characterized cis-regulatory elements (en-
hancers) that directly regulate differential expression at
the angiogenic front in vivo has presented a major chal-
lenge when attempting to identify direct gene targets
of transcriptional and signaling angiogenic networks.
Many studies have focused instead on putative regulatory
sequences identified by proximity to the core promoter.
For example, multiple studies have focused on the Dll4
promoter region (Hayashi and Kume 2008; Roukens
et al. 2010; Corada et al. 2013; Lizama et al. 2015), al-
though recent transgenic mouse and zebrafish analyses
have demonstrated that this region is neither sufficient
nor required for Dll4 expression in vivo (Sacilotto et al.
2013; Wythe et al. 2013). A large body of work has now
clearly determined that complex patterns of gene expres-
sion require multiple interactions between promoter and
enhancer elements, the latter usually located away from
the core promoter (for example, Kieffer-Kwon et al.
2013), stressing the need for a greater focus on distal en-
hancer regions when studying transcriptional pathways.
Here we describe the first enhancer capable of directing
precise, differential gene activity during angiogenic
sprouting. By investigating the regulation of this enhanc-
er, we uncovered an unexpected and essential role for
MEF2 transcription factors in the regulation of Dll4
gene expression in tip cells and in the activation of gene
expression during sprouting angiogenesis more generally
in both physiological and pathological vascular growth.
Results
The Dll4 enhancer Dll4in3 directs expression
to endothelial cells during sprouting angiogenesis
Previously, two arterial enhancers for the Notch ligand
Dll4 have been described: one located within the third in-
tron (referred to here as the Dll4in3 enhancer) (Sacilotto
et al. 2013; Wythe et al. 2013) and the other located 12
kb upstream of the transcriptional start site (Dll4-12 en-
hancer) (Sacilotto et al. 2013). Similar to endogenous
Dll4, both enhancers were active in arterial but not
venous endothelial cells, an expression pattern precisely
regulated by ETS, RBPJ, and SOXF transcription factors
(Sacilotto et al. 2013; Wythe et al. 2013). However, endog-
enousDll4 is also expressed in tip cells leading the forma-
tion of new vessel sprouts. Consequently, we investigated
whether theseDll4 enhancers were able to direct reporter
gene expression during sprouting angiogenesis. We
detected Dll4in3-driven LacZ reporter gene activity in
angiogenic vessels in a pattern closely mimicking that
of endogenous Dll4, including expression in endothelial
cells undergoing sprouting angiogenesis within the hind-
brain at embryonic day 11 (E11) and in the postnatal retina
(Fig. 1 A; Supplemental Fig. 1A–C). The reporter gene
expression at the angiogenic front in the retina was speci-
fic and persisted throughout sprouting angiogenesis
(Supplemental Fig. 1C).
Dll4in3 and Dll4-12 enhancers both contain the
ETS-, RBPJ-, and SOXF-binding motifs essential for
arterial expression (Sacilotto et al. 2013). Consequently,
we investigated whether the Dll4-12 enhancer could
also drive expression in the angiogenic sprout. However,
although Dll4-12:LacZ activity appeared equally robust
in arterial endothelial cells at both embryonic and postna-
tal stages, no transgene activity could be detected in en-
dothelial cells undergoing active angiogenesis (Fig. 1B;
Supplemental Fig. 1D,E). E11 hindbrains frommultiple in-
dependent transgenic founders were examined to exclude
the possibility of influences downstream from transgene
insertion (Supplemental Fig. 1D). These results demon-
strate that the Dll4in3 enhancer contains DNA sequences
that convey unique transcriptional information and sug-
gest that gene expression in sprouting angiogenesis is reg-
ulated by factors other than, or in addition to, ETS, RBPJ,
and SOXF.
MEF2 transcription factors regulate Dll4 enhancer
expression during sprouting angiogenesis in both
physiological and pathological vessel growth
A comparison of the Dll4in3 and Dll4-12 enhancer se-
quences demonstrated that the angiogenic Dll4in3 en-
hancer contained consensus MEF2- and Forkhead C
(FOXC)-binding motifs that were not present in the Dll4-
12 sequence (Fig. 2A; Supplemental Fig. 2A,B). The
Dll4in3 MEF2-binding motif bound MEF2A, MEF2C,
and MEF2D proteins in electophoretic mobility shift
assay (EMSA) and chromatin immunoprecipitation (ChIP)
analysis (Supplemental Fig. 2C–E; Sacilotto et al. 2013;
Wythe et al. 2013), whereas the putative FOX motif did
not bind FOXCproteins in EMSAandhadnodetectable ef-
fect on Dll4in3:LacZ expression at E11 (Sacilotto et al.
2013). We therefore examined the role of the Dll4in3
MEF2-binding motif in enhancer activity in transgenic
mice. Although mutation of the MEF2-binding motif pre-
sent in Dll4in3 (Fig. 2B) had no effect on reporter gene ex-
pression in arterial endothelial cells (Fig. 2C; Sacilotto
Sacilotto et al.
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et al. 2013; Wythe et al. 2013), loss of MEF2 binding led
to an almost total loss of reporter gene expression in em-
bryonic hindbrains and postnatal retinas during sprouting
angiogenesis (Fig. 2C; Supplemental Fig. 2F,G). These re-
sults therefore indicate that theMEF2-bindingmotifwith-
in the Dll4in3 enhancer is essential for directing gene
expression in endothelial cells undergoing active sprout-
ing angiogenesis.
Sprouting angiogenesis also occurs in the adult in re-
sponse to physiological cues that support cycles of remod-
eling and repair and in pathological conditions, including
cancer, where establishment of a vascular system is essen-
tial for tumour growth and metastasis (Kerbel 2008).
Therefore, we examined the expression of the Dll4in3
enhancer during neovascular growth in adult mice.
Similar to developmental angiogenesis, the Dll4in3:
LacZ enhancer was able to direct reporter gene expres-
sion to new vessels during Matrigel plug and B16F10
melanoma-stimulated neovascularization (Fig. 3A;
Supplemental Fig. 3A,B). As with the postnatal day 6
(P6) retina, expression was not detected in every endothe-
lial cell (Supplemental Fig. 3A); instead, the pattern close-
ly resembled that reported in Unc5bLacZ/+ mice, in which
LacZ expression correlated with sprouting angiogenesis
(Larrivee et al. 2007). Strikingly, mutation of the MEF2-
binding motif within the Dll4in3 enhancer resulted in a
total loss of reporter gene expression during neoangiogen-
esis (Fig. 3B; Supplemental Fig. 3C,D) despite the mainte-
nance of transgene expression in the vasculature of some
adult organs (Supplemental Fig. 3E). These results clearly
demonstrate the importance of the MEF2-binding motif
for Dll4 enhancer expression during both physiological
and pathological angiogenesis.
MEF2 factors regulate endogenous DLL4 expression
We demonstrated previously that RBPJ and SOXF factors,
both of which are essential for Dll4in3 enhancer activity
in arterial endothelium, were also required for expression
of the endogenousDll4 gene and the acquisition of arterial
fate more generally (Sacilotto et al. 2013). We therefore in-
vestigated whether MEF2 transcription factors regulate
endogenous Dll4 during sprouting angiogenesis. Al-
though MEF2 transcription factors have been implicated
in vascular integrity and endothelial cell survival (Haya-
shi et al. 2004; Olson 2004; Chang et al. 2006), endotheli-
al-specific ablation of MEF2C resulted in no detected
embryonic defects (Xu et al. 2012) and did not alter
Dll4in3 or endogenous Dll4 expression in early develop-
ing arteries (Wythe et al. 2013). However, Mef2Cfl/null;
Tie2Cre/+ mice did exhibit increased vascular sprouting af-
ter oxygen-induced retinopathy, resembling Dll4LacZ/+
mice after similar insult (Lobov et al. 2007; Xu et al.
2012). All MEF2 factors bind a similar DNA motif and
can be functionally redundant (Potthoff and Olson 2007;
Liu et al. 2014). Since MEF2A, MEF2C, and MEF2D
were each able to directly bind the Dll4in3 MEF2 motif
(Supplemental Fig. 2D,E), we hypothesized that multiple
MEF2 factors may regulate Dll4 expression. Supporting
this, we detected expression of MEF2A, MEF2C, and
MEF2D in endothelial cells from multiple tissues and
with expression dynamics correlating to that ofDll4 after
VEGFA (Fig. 4A,B; Supplemental Fig. 4A–D). Combined
siRNA-mediated knockdown of MEF2A,C and MEF2D
in human umbilical vein endothelial cells (HUVECs) re-
sulted in significantly reduced Dll4 expression after
VEGFA stimulation (Fig. 4C,D; Supplemental Fig. 4E,F).
Furthermore, theseMEF2 knockdown HUVEC cells dem-
onstrated a reduction of tip cell competitiveness com-
pared with control cells in VEGFA-induced mosaic
spheroid sprouting assays (Supplemental Fig. 5A,B). The
Figure 1. TheDll4in3 enhancer directs gene expression to endo-
thelial cells during sprouting angiogenesis. (A) Representative
images from Dll4in3:LacZ transgenic mice demonstrate enhanc-
er activity in endothelial cells undergoing sprouting angiogenesis
in the E10 embryo, E11 hindbrain, and postnatal day 6 (P6) retina.
(B) Representative images from Dll4-12:LacZ transgenic mice
demonstrate enhancer activity in arterial and neural tissues but
no activity in endothelial cells during sprouting angiogenesis in
E10 embryos, E11 hindbrains, or postnatal retinas. Enhancer ac-
tivity was detected as X-gal activity (blue staining or green pseu-
docolor), and endothelial cells were detected by isolectin B4 (IB4)
whole-mount immunostaining (red). (a) Artery; (sa) region of
sprouting angiogenesis; (n) neuronal staining. See also
Supplemental Figure 1.
Regulation of sprouting angiogenesis by MEF2
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same phenotype was observed in VEGFA-induced sprout-
ing of embryoid bodies after CRISPR/Cas9-mediated abla-
tion of Mef2A and Mef2C in embryonic stem (ES) cells
(Supplemental Fig. 5C–E). This reduced competitiveness
was similar to previous reports demonstrating that
Dll4LacZ/+ heterozygous ES cells with reduced DLL4
levels cannot compete with wild-type cells for the tip
cell position during sprouting angiogenesis (Jakobsson
et al. 2010).
To investigate whether depletion of MEF2 factors had a
repressive effect onDll4 expression in vivo, we next inves-
tigated the expression levels of DLL4 in mice after endo-
thelial-specific induced deletion of Mef2A and Mef2C
[Cdh5(PAC)Cre-ERT2;Mef2Afl/fl;Mef2Cfl/fl, denoted as in-
duced endothelial cell-specific (iEC)Mef2A/C knockout].
Although Mef2D was not targeted in these mice, DLL4
levels were reduced in the highly angiogenic E11 hind-
brains 3 d after induction of gene deletion (Fig. 4E), and
substantially less DLL4 was detected at the angiogenic
front in P5 retinas 4 d after the induction of gene deletion
(Fig. 4F). Analysis of whole-lung extracts confirmed the
significant decrease in Dll4 transcript levels concurrent
with reduction inMef2A andMef2C despite the inclusion
of nonvascular cells in this analysis (Fig. 4G). These re-
sults therefore support a key role for MEF2 factors in the
regulation of endogenousDll4 during sprouting angiogen-
esis and consequently on the differentiation of tip cells
during this process.
MEF2 factors directly regulate many genes during
sprouting angiogenesis
Although Dll4 expression was clearly reduced after in-
duced endothelial deletion of Mef2A/C, it was notable
that iEC Mef2A/C knockout P5 retinas did not exhibit
the increased levels of sprouting angiogenesis and vessel
branching reported as a consequence of Notch inhibition
or Dll4 reduction alone (Hellström et al. 2007). Instead,
iECMef2A/C knockout retinas displayed a vascular plex-
us with a significant reduction of vascular density and
coverage accompanied by a reduced number of tip cells
at the angiogenic front (Fig. 5). These results indicate
that the loss of MEF2A/C results in an overall reduction
of angiogenic sprouting and point to a potential role for
MEF2 in regulating vascular growth more generally.
To establish whetherMEF2 factors directly regulate other
angiogenesis-related genes and consequently the angio-
genic process more generally, we analyzed genome-wide
MEF2C-binding peaks associated with enhancer-specific
histone marks in HUVECs from publicly available ChIP-
seq (ChIP combined with high-throughput sequencing)
data (Maejima et al. 2014). Supporting our earlier analysis,
the Dll4in3 enhancer region contained a robust MEF2-
binding peak, whereas no similar peak was found around
the Dll4-12 nonangiogenic enhancer or elsewhere in the
Dll4 locus (Supplemental Fig. 6A). Pan-genomic analysis
of MEF2C-binding locations revealed a significant enrich-
ment of enhancer-associated MEF2C binding near genes
known to be up-regulated during sprouting angiogenesis
(Fig. 6A,B; Supplemental Fig. 6B; Supplemental Tables 1,
Figure 2. The Dll4in3 enhancer contains a MEF2-binding motif
that is required for expression during sprouting angiogenesis. (A)
Schematic representation of the binding motifs found within the
mouse Dll4in3 and Dll4-12 enhancer sequences. Colored shapes
represent sequences directly verified by EMSA analysis
(Supplemental Fig. 2; Sacilotto et al. 2013), and gray shapes indi-
cate consensus or near-consensus sequences that did not bind the
cognate transcription factors in EMSA. (B) Schematic representa-
tion of the Dll4in3mutMEF enhancer sequence in which the
MEF2-binding motif within the Dll4in3 enhancer has been mu-
tated. (C ) Representative images fromDll4in3mutMEF transgen-
ic mice demonstrate that this enhancer does not direct
endothelial expression during sprouting angiogenesis in E10 em-
bryos, E11 hindbrains, or P6 retinas, although robust expression is
detected in the arterial (a) and neuronal (n) compartments. See
also Supplemental Figure 2.
Sacilotto et al.
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2; del Toro et al. 2010; Strasser et al. 2010), suggesting a
role for MEF2 factors in angiogenic gene activation be-
yondDll4 and providing a potential explanation for the de-
creased vascular growth seen in the iEC Mef2A/C
knockout retinas. No enhancer-associated MEF2-binding
peaks were found within 200 kb of any other Notch path-
way gene, including JAG1, JAG2,HES1,HEY1, andHEY2
(Supplemental Fig. 6C). Loci containing significantMEF2-
binding peaks included the transcription factors ETS1,
ELK3, andHLX, all of which are also implicated in the reg-
ulation of angiogenic behavior (Fig. 6C; De Val and Black
2009; Herbert et al. 2012). The human DNA sequences
around these sites were tested in mosaic transgenic zebra-
fish at 26–30 h post-fertilization (hpf), confirming that
they were bona fide angiogenic enhancers (Fig. 6D).
The MEF2C-bound enhancer element 3 kb upstream of
the HLX gene (HLX-3 enhancer) (Supplemental Fig. 7A)
was particularly notable, asHLX/hlx expression is unusu-
ally specific to sprouting angiogenesis (Herbert et al. 2012;
Prahst et al. 2014). Furthermore, HLX expression is also
known to be downstream from VEGFA stimulation
through EP300 binding at the same location where
MEF2C was bound (Supplemental Fig. 7A; Zhang et al.
2013). We confirmed the sprout-specific expression pat-
tern of this enhancer in a stable zebrafish transgenic line,
tg(hlx-3:GFP) (Fig. 5E). This enhancer contained three
MEF2 sites (Supplemental Fig. 7B), the strongest of which
was able to bind MEF2A, MEF2C, and MEF2D in EMSA
analysis at levels comparablewith theDll4in3MEF2motif
(Supplemental Fig. 8).Mutationof theseMEF2 sites result-
ed in total ablation of transgene expression in both trans-
genic zebrafish and mice (Fig. 6F,G; Supplemental Fig.
7C,D). Together, these results suggest that MEF2 factors
play a crucial role in the transcriptional activation of mul-
tiple genes associated with sprouting angiogenesis.
MEF2 regulates tip cell genes downstream from VEGFA-
mediated histone deacetylase (HDAC) derepression
Our data support a role for MEF2 factors in the activation
of sprouting angiogenesis downstream from VEGFA sig-
naling in endothelial cells. We therefore next investigated
themechanisms bywhichMEF2 factors are able to specif-
ically activate gene transcription in sprouting, but not
quiescent, endothelial cells. Although the transcriptional
regulators ofMef2a andMef2d in endothelial cells remain
unknown,Mef2c transcription is known to be directly ac-
tivated by ETS factors, including ETS1 (DeVal et al. 2004).
Therefore, MEF2 factors may lie at the top of a feed-for-
ward loop during sprouting angiogenesis, activating the
expression of Ets factors, which would then reinforce
Mef2 expression and also collaborate with MEF2 factors
in the activation of downstream sprouting angiogenic
genes, including Dll4. This model is supported by our ob-
servations that mRNA and protein levels of MEF2A and
MEF2C notably increase after VEGFA stimulation (Fig.
4B; Supplemental Fig. 4C).
However, this feed-forward loop is unlikely to be the
onlymechanism: TheMef2c enhancer itself is not specific
to sprouting angiogenesis (De Val et al. 2004), ETS factors
are essential for all endothelial gene expression (De Val
and Black 2009; Randi et al. 2009), and MEF2 proteins
can be detected in most endothelial cells (Fig. 4A;
Supplemental Fig. 4A). Furthermore, ChIP analysis dem-
onstrates that MEF2 factor binding to the DLL4in3 and
HLX-3 enhancers occurs independently of VEGFA stimu-
lation (Supplemental Fig. 9A,B), although both HLX ex-
pression (Testori et al. 2011) and DLL4 expression (Fig.
4B) are significantly up-regulated only after VEGFA stim-
ulation. Therefore, we hypothesized that the ability of
MEF2 factors to associate with transcriptional coactiva-
tors may bemodified by VEGFA stimulation. The histone
acetyltransferase EP300 has been shown to play a key role
in transcriptional activation downstream from VEGFA
in endothelial cells, where it is tightly associated with
the enhancer-associated histone modification H3K27ac
(Zhang et al. 2013). We therefore tested the dynamics of
EP300 recruitment to the Dll4in3 enhancer and found a
significant increase in binding after VEGFA stimulation
(Fig. 7A). This result suggests that the ability of MEF2 fac-
tors to activate gene expression was affected directly by
VEGFA-induced recruitment of EP300.
The activity of MEF2 factors in other cell types is
known to bemodulated by themutually exclusive recruit-
ment of EP300 and class II HDACs (Lu et al. 2000; Youn
et al. 2000). Class II HDACs inhibit MEF2 factors by
directly binding to them and consequently preventing
the ability of MEF2 to recruit cofactors required for gene
activation (Lu et al. 2000; Chan et al. 2003). Since VEGFA
stimulation is known to directly induce class IIa HDAC
Figure 3. The Dll4in3 enhancer requires
MEF2 binding to direct expression during
adult neovascularization. (A) Representa-
tive images of Dll4in3:LacZ transgene ex-
pression during neovascularization into
Matrigel plugs and B16F10 melanoma tu-
mors demonstrate robust vascular X-gal
staining. (B) Representative images of the
mutant Dll4in3mutMEF:LacZ transgene
demonstrate that the mutated enhancer
was unable to direct any detectable reporter
gene expression during adult neovasculari-
zation. See also Supplemental Figure 3.
Regulation of sprouting angiogenesis by MEF2
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Figure 4. MEF2 factors regulate endogenous Dll4 expression and tip cell identity. (A) Whole-mount immunostaining demonstrates ex-
pression of MEF2A,MEF2C, andMEF2D transcription factors in endothelial cells from E11 hindbrains and in HUVECs. Bars, 100 μm. (B)
Western blot analysis of MEF2A, MEF2C, MEF2D, and DLL4 expression in HUVECs 1 min to 8 h after VEGFA stimulation. Representa-
tive of four repeats. (C ) RNAi-mediated knockdown ofMEF2A,MEF2C, andMEF2D factors by pooled siRNAs in HUVECs results in loss
of DLL4 expression, while VEGFR2 expression remains unaffected. (NS) Nontargeting control siRNA. Representative of two repeats. (D)
Relative gene expression levels ofDLL4,MEF2A,MEF2C, andMEF2D analyzed by quantitative RT–PCR (qRT–PCR) after RNAi-mediated
knockdown and 1 h of VEGFA stimulation. Statistical analysis was performed on four biological replicates. Error bars indicate standard
deviation. (E) Induced endothelial cell-specific (iEC)Mef2A/C double knockouts (Mef2A/C KO) show a significant reduction in DLL4 ex-
pression, as detected by Western blot of E12 hindbrain extracts. Cre recombination was induced by tamoxifen injection in pregnant mice
at E9. (Ctrl) Cre-negative; (1–4) four different iEC Mef2A/C knockout littermates. Note the variability in DLL4 reduction among litter-
mates, as expected from Cre recombination in response to tamoxifen. Comparative band intensity was normalized to ACTB levels and
made relative to wild type. (F ) Endogenous DLL4 expression (green) in representative control (Cre-negative) and iECMef2A/C knockout
P5 retinas at the angiogenic front. All endothelial cells were detected by IB4whole-mount immunostaining (red). (G) Relative gene expres-
sion levels ofDLL4,MEF2A,MEFC, andMEF2D analyzed by qRT–PCR in five different P5 lungs taken fromcontrol (Cre-negative;CT) and
knockout (iECMef2A/C KO) pups. Three technical replicates were used for each pup. Error bars indicate standard deviation.
Sacilotto et al.
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phosphorylation and cytoplasmic accumulation (Ha et al.
2008a,b), we hypothesized that this may be the mecha-
nism through which VEGFA signaling at the angiogenic
front directly activates MEF2. ChIP analysis confirmed a
significant decrease in binding of the class IIa HDACs
HDAC4, HDAC7, and HDAC9 to the DLL4in3 enhancer
after VEGFA stimulation (Fig. 7B). Furthermore, general
inhibition of HDAC activity by trichostatin A (TSA) re-
sulted in a significant increase in DLL4 transcription in
HUVECs (Fig. 7C) and Dll4in3 enhancer activity both in
vivo (Fig. 7D) and ex vivo (Supplemental Fig. 9C). To con-
firm that the repressive activity of HDACs on DLL4 ex-
pression occurred directly via MEF2 interaction, we
tested the effects of two different small molecule inhibi-
tors of class IIa HDACs. BML-210 works by specifically
targeting and disrupting the MEF2:HDAC complex (Jaya-
thilaka et al. 2012), whereas MC-1568 instead selectively
stabilizes this complex (Nebbioso et al. 2009). Supporting
the hypothesis that MEF2:HDAC binding directly inhib-
its DLL4 expression in nonangiogenic cells, treatment
with BML-210 resulted in a significant increase in DLL4
transcription that is mirrored by that ofMMP10, a known
MEF2 target regulated by MEF2:HDAC interaction (Fig.
7E; Chang et al. 2006; Ha et al. 2008a). Conversely, treat-
ment with MC-1568 did not increase DLL4 and MMP10
expression (Fig. 7E). Other genes known to be up-regulated
or down-regulated byTSA in the presence of VEGF (Rafehi
et al. 2014) butwithout aMEF2C-binding peakwithin 200
kb were not significantly affected by these compounds
(Supplemental Fig. 9D).
In conclusion, these results support a model (Fig. 7F) in
which VEGFA-triggered release of repressive HDACs and
concurrent recruitment of the activating histone acetyl-
transferase EP300 to MEF2-bound enhancers results in
MEF2-activated transcription of immediate downstream
angiogenic target genes, including multiple ETS factors.
This further reinforces the expression of Mef2 genes
though a feed-forward loop, enhances the angiogenic tran-
scriptional cascade, and drives the high levels of Dll4 ex-
pression required to form a leading tip endothelial cell.
This activation ofNotch signaling then triggers the lateral
inhibition and guided vascular patterning essential for
sprouting angiogenesis.
Discussion
It is well established that endothelial sprouting is con-
trolled by VEGF signaling (Gerhardt et al. 2003). However,
VEGF receptors use multiple signal transduction path-
ways and transcriptional effectors to obtain strikingly dif-
ferent vascular outcomes, and therefore the manner in
which high levels of VEGFA establish the precise gene ex-
pression patterns required for sprouting angiogenesis has
been a key question in vascular biology. In this study,
we demonstrate that VEGFA-induced gene expression in
endothelial cells at the angiogenic front is downstream
fromMEF2 factor-driven transcriptional activation. In ad-
dition to their roles in the endothelium, MEF2 factors are
widely expressed in nonvascular tissues and play crucial
roles in the development of cardiac and skeletal muscle,
bone, neural crest, and T cells (Potthoff and Olson 2007).
Consequently, it is likely that they collaborate with other
transcription factors to achieve endothelial-specific re-
sponses. One potential partner is the ETS family of tran-
scription factors. All angiogenic enhancers characterized
in this study contained multiple ETS motifs in addition
to MEF2 sites. Furthermore, loss of ETS motifs ablated
Figure 5. Induced endothelial deletion ofMef2A and Mef2C re-
sults in reduced retinal angiogenesis. (A) Representative P5 and
P6 retinas taken from control (Cre-negative) and iEC Mef2A/C
knockout (KO) pups and stained for IB4. Tip cells were detected
by filopodia and are indicated by asterisks. The white box indi-
cates region taken for zoom image. Bars, 1 mm. (B) Graphs dem-
onstrating the mean number of tip cells, the ratio of the mean
number of branch points, and themean outgrowth length asmea-
sured by actual distance covered by the growing vessel from the
center of the retina. Statistical analysis was performed on seven
wild-type and nine knockout pups pooled from two different
litters.
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Dll4in3 expression in both arteries and sprouting angio-
genesis (Sacilotto et al. 2013; Wythe et al. 2013), suggest-
ing that ETS factors cooperate with MEF2 factors in the
vasculature. This is supported by the observation that
ETS factors are both transcriptional activators of and acti-
vated by MEF2C (Fig. 6; De Val et al. 2004). Of note, the
highly endothelial-expressed ETS transcription factor
ERGhas been implicated in the regulation ofDll4 in arter-
ies downstream from VEGFA (Wythe et al. 2013) and in
vascular growth, including in the angiogenic retina (Bird-
sey et al. 2015). However, it is unlikely that ERG or other
ETS factors regulate angiogenic gene expression alone:
Unlike MEF2 motifs, ETS-binding motifs are found in
all known endothelial enhancers and promoters regard-
less of expression pattern within the vasculature (De Val
and Black 2009), and ERG itself is expressed widely
throughout the endothelium (Randi et al. 2009). Further-
more, we demonstrate here that Dll4in3 and HLX-3 en-
hancers with intact ETS motifs were unable to drive
angiogenic expression after MEF2 motif ablation, al-
though Dll4in3 was still able to drive arterial expression.
Similarly, the wild-type Dll4-12 enhancer containing
multiple functional sites for ETS but no MEF2 sites was
unable to drive anything other than arterial expression.
These results therefore instead support a model in which
MEF2 factors cooperate with ETS factors, with ETS pro-
viding essential endothelial expression information, and
MEF2 contributing to angiogenic sprout specificity.
The SOXF family of transcription factorsmayalso play a
role in MEF2-driven angiogenic gene activity. Unlike the
widely expressed ETS andMEF2 factors, the SOXF factors
(SOX7, SOX17, and SOX18) are primarily restricted to ar-
terial and angiogenic endothelial cells in mammals (Cor-
ada et al. 2013; Lee et al. 2014). SOXF factors have
already been implicated in the regulation of Dll4/Notch
signaling (Corada et al. 2013; Sacilotto et al. 2013), but
their precise role at the angiogenic front is not yet estab-
lished. SOXF binding in combination with ETS factors is
likely not sufficient for angiogenic expression, asmultiple
enhancers, including Dll4-12 and Ece1, robustly bind
SOXF and ETS factors but do not drive expression during
sprouting angiogenesis (Robinson et al. 2014). However,
loss of SOX17 affected sprouting angiogenesis in the retina
(Corada et al. 2013; Lee et al. 2014), and a role for SOXF fac-
tors in combination with MEF2 cannot be ruled out: The
Dll4in3 MEF2 motif is adjacent to a functional SOXF-
binding motif, and MEF2C is known to directly interact
with SOX18 (Hosking et al. 2001). It would therefore be
fascinating to directly compare the global binding patterns
of SOX7, SOX17, and SOX18 with MEF2 factors in endo-
thelial cells and establish the role of SOXF-binding motifs
in our newly identified set ofMEF2-dependent angiogenic
enhancers.
In addition to collaborative binding with other tran-
scription factors, our data also indicate that the specificity
of MEF2 activation to sprouting angiogenesis is modulat-
ed by the removal of repressive class IIa HDAC binding
and recruitment of EP300 downstream from VEGFA.
However, MEF2 factors are able to confer signal respon-
siveness downstream from multiple signaling pathways.
Figure 6. MEF2 binding is a shared feature ofmany angiogenesis
enhancers. (A,B) MEF2C-binding peaks are enriched around 200
kb of genes associated with sprouting angiogenesis, as assessed
by increased expression in the hypersprouting retina of Dll4+/−
mice (P = 8.682 × 10−09) (del Toro et al. 2010) (A) or identified
through laser capture microdissection of retinal tip cells (P =
0.007776) (Strasser et al. 2010) (B). (C ) Genomic snapshots denot-
ingMEF2C-binding siteswithin the loci forHLX, ETS1, and ELK3
transcription factors. H3K27ac peaks are indicated in green,
MEF2C-binding peaks are indicated in red, and novel angiogenic
enhancers are indicated in black. (D) tol2-mediatedmosaic zebra-
fish transgenic for the human MEF2C-binding peak enhancers
HLX-3, ETS1+194, and ELK3-29 demonstrate enhancer-driven
GFP expression in sprouting endothelial cells (green). (ISV) Inter-
segmental vessels. (E) The stable transgenic zebrafish line tg(hlx-
3:GFP) directs expression specifically to sprouting endothelial
cells in the intersegmental vessels. (F ) Summary of reporter
gene expression detected in 32-hpf tol2-mediated mosaic tran-
sient transgenic zebrafish embryos. (G) Whole-mount embryos
and hindbrains of representative E11 X-gal-stained transient
transgenic embryos expressing HLX-3 wild-type:LacZ and HLX-
3mutMEF:LacZ transgenes. See also Supplemental Figures 6–8.
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For example, multiple calcium-regulated protein kinases
are able to modulate HDAC binding to MEF2 factors,
and phosphorylation by MAP kinases can activate MEF2
(Potthoff andOlson 2007; Ge et al. 2009). The latter is par-
ticularly notable given that recent work implicates ERK
as a specific effector of Vegfa signaling in the induction
of angiogenic genes during sprouting (Shin et al. 2016).
Furthermore, research in skeletal muscle also demon-
strated that the MEF2 proteins can compete with NICD
for binding to the MAML coactivator (Shen et al. 2006),
suggesting that high levels of NICD in stalk cells may
also have a repressive effect on MEF2 factors in the endo-
thelium, reinforcing the lateral inhibition. Consequently,
it is very likely thatMEF2 transcriptional activity is mod-
ulated by a complex combination of transcriptional, trans-
lational, and post-translationalmodifications, all of which
contribute to the gene expression pattern downstream
from VEGF receptor signaling.
Previous work has already implicated MEF2 transcrip-
tion factors in the maintenance of vascular integrity via
HDAC7-mediated MMP10 repression and downstream
from BMK1 (Hayashi et al. 2004; Olson 2004; Chang
et al. 2006). Although these reports principally focused
onMEF2Cat least in part due to the cardiovascular pheno-
types reported in the global MEF2C-null mice (Lin et al.
1998; Bi et al. 1999), endothelial-specific ablation of
MEF2C resulted in no clear embryonic vascular defects
(Xu et al. 2012). This result indicates that the vascular de-
fects seen in the globalMEF2C-null micewere principally
downstream from cardiac dysfunction and suggests that
MEF2 factor redundancy in the vasculature extends be-
yond the regulation ofDll4. Thismaymirror the situation
in skeletal muscle regeneration, where an absolute re-
quirement for MEF2 was revealed only after compound
deletion of Mef2A, Mef2C, and Mef2D (Liu et al. 2014).
However, although loss of endothelial MEF2C had no de-
tected effects in physiological conditions, Xu et al. (2012)
reported a significant increase in vascular recovery and a
cognate decrease in pathological neovascularization in
the Mef2C-null retinal vasculature after oxygen-induced
retinopathy, indicating that loss of MEF2C results in in-
creased sprouting after injury. These results, which corre-
late with work demonstrating reduced in vitro VEGFA-
induced vascular sprouting after MEF2C overexpression
(Sturtzel et al. 2014), are in agreement with the conse-
quences of Dll4 perturbations: Reduced DLL4 levels re-
sult in increased retinal vascular recovery and decreased
neovascularizion after oxygen-induced retinopathy (Xu
et al. 2012) and increased sprouting in response to VEGFA
(Sainson et al. 2005; Jakobsson et al. 2010), while overex-
pression ofDLL4 reduces the in vitro responses to VEGFA
(Williams et al. 2006). Therefore, we hypothesize that
even limited reductions of Dll4 levels downstream from
MEF2C perturbation disrupt Notch-mediated lateral inhi-
bition, resulting in hypersprouting in conditions of patho-
logical stress.
Functional redundancy within the MEF2 family may
not be the only contributor to the variable phenotypes
seen after Mef2 gene deletion. The multiple targets of
MEF2 factors in the vasculature, particularly those in-
volved in angiogenic sprouting, may also contribute to
the challenges in detecting and understanding phenotypic
changes after MEF2 factor modulation. The reduced vas-
cular density, coverage, and tip cell numbers seen in iEC
MEF2A/C retina vasculature would initially appear oppo-
site to the hypersprouting seen after Dll4 reduction,
Figure 7. VEGFA signaling leads to activa-
tion of MEF2 transcriptional activity. (A)
Increased EP300 binding at theDLL4in3 en-
hancer after VEGFA stimulation in
HUVECs analyzed by ChIP. Graph is repre-
sentative of four biological replicates. (B)
Decreased class II HDAC binding at the
DLL4in3 enhancer after VEGFA stimula-
tion in HUVECs analyzed by ChIP. The
graph is representative of two biological
replicates. (C ) Relative DLL4 gene expres-
sion after VEGFA stimulation with and
without trichostatin A (TSA), analyzed by
qRT–PCR. Statistical analysis on four bio-
logical replicates. Error bars indicate stan-
dard deviation. (D) Representative
Dll4in3:LacZ E13 hindbrains removed 24
h after in utero intracerebral injection of
10 μMHDAC inhibitor TSA or DMSO con-
trol. X-gal staining after DMSO control in-
jection is weak, whereas more robust
transgene expression was detected in hind-
brains injected with TSA. (E) Relative gene
expression levels ofDLL4 andMMP10 after
VEGFA stimulation with and without
treatment with small molecule class II HDAC inhibitors BML-210 and MC-1568, analyzed by qRT–PCR. Statistical analysis was per-
formed on three biological replicates. Error bars indicate standard deviation. (F ) Proposedmodel of VEGFA-mediated activation of sprout-
ing angiogenesis via the MEF2 transcription factor family. See also Supplemental Figure 9.
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although reduced Dll4 expression was consistently seen
in these mice. However, this phenotype must be consid-
ered in light of other roles for MEF2 factors in the vascula-
ture. MEF2 has been implicated in the regulation of
vascular integrity downstream from MMP10 activation
and in the activation of the transcription factors KLF2
and KLF4 (Parmar et al. 2006;Maejima et al. 2014), impor-
tant regulators of inflammation, vascular tone, and stabi-
lization (Atkins and Jain 2007). Additionally, our work
here demonstrates a direct link between MEF2 factor
andmany other genes involved in sprouting angiogenesis.
The challenge in understanding the phenotypes after
Mef2 ablation comes because individual loss of different
genes required during sprouting angiogenesis can result
in vastly different consequences. While depletion of Dll4
levels can have a proangiogenic effect, loss or depletion
of direct MEF2 targets ETS1, ELK3, and HLX can have
anti-angiogenic effects in vivo (Pham et al. 2007; Wei
et al. 2009; Herbert et al. 2012; Weinl et al. 2014). Further-
more, the vascular Notch pathway genes disregulated by
DLL4 reduction are themselves, like all other vascular
genes, likely to be direct ETS factor targets, suggesting
that the hypersprouting routinely seen after Dll4 disrup-
tion may also be indirectly repressed by the general sup-
pression of MEF2–ETS–Notch pathway gene activation.
Consequently, while the balance of pro- and anti-angio-
genic signaling appears perturbed only inMEF2C-null ret-
ina when pathologically stressed, the compound loss of
MEF2A/C appears to tip the balance into an anti-angio-
genic response, albeit one potentially mitigated by the
maintained MEF2D signaling and possibly the disruption
of Dll4-mediated lateral inhibition. These results also
serve to illustrate the challenges of interpreting knockout
animal models when studying transcription factors with
multiple targets, particularly when redundancy must
also be considered.
In conclusion, our work demonstrates that the analysis
of enhancers can be a powerful approach to study the het-
erogeneity and complexity of signaling networks operat-
ing in angiogenesis in a variety of different settings.
Materials and methods
Cloning
The Dll4in3, Dll4in3mutMEF2, and Dll4-12 enhancers were as
described previously (Sacilotto et al. 2013). The ETS1+194,
ELK3-29, HLX-3, HLX-3mutMEF2, hlx-3, and hlx-3mutMEF en-
hancers were generated as custom-made, double-stranded linear
DNA fragments (GeneArt Strings, Life Technologies). Reporter
vectors were generated using Gateway technology (Invitrogen).
Animals
All UK animal procedures were approved by local ethical review
and licensed by the UKHomeOffice. US animal procedures com-
plied with US federal and institutional guidelines. Transgenic
micewere generated by oocytemicroinjection.Mosaic transgenic
zebrafish embryos were generated using the tol2 system (Kawa-
kami 2005), and GFP reporter expression was scored at 32 hpf.
The tg(hlx-3:GFP) stable line was created by outcross of adult
F0 carriers generated using the tol2 system. X-gal analysis of em-
bryos and postnatal organs was as described (De Val et al. 2004).
X-gal analysis in retinas was as described (Jakobsson et al.
2010), and hindbrains were dissected as described (Fantin et al.
2013) and treated like the embryos. ForMatrigel assays, transgen-
ic mice were subcutaneously injected into the flanks with BD
Matrigel basement membrane matrix (BD) supplemented with
2 µg/mL fibroblast growth factor (Peprotech) and harvested 14 d
after injection. For tumors, transgenic mice were subcutaneously
injected with 100 µL of BDMatrigel basement membrane matrix
(BD) containing 1 × 105 B16F10 melanoma cells and harvested at
12-mmdiameter. iECMef2A/Cknockout embryos and pupswere
obtained by crossing Mef2Aflox/flox;Mef2Cflox/flox mice (Vong
et al. 2005; Akhtar et al. 2012) with Cdh5(PAC)Cre-ERT2 mice
(Wang et al. 2010). Recombination was induced by tamoxifen in-
jection in pregnantmice 9 d after a plug was detected, and embry-
os were harvested 3 d later, genotyped, and fixed in 4% PFA for 2
h. For postnatal analysis, tamoxifen injection occurred at P1, P2,
and P3, and retinas and lungs were harvested at P5 and P6. Eyes
were removed from pups, fixed with 4% PFA for 90 min, and
rinsed in PBS, and then the retinas were dissected as described
previously (Pitulescu et al. 2010). Whole lungs were also dissect-
ed, rinsed in PBS, and then snap-frozen in liquid nitrogen for sub-
sequent RNA extraction.
Western blot
HUVECpelletswere lysed in RIPA buffer (50mMTris-HCL at pH
7.4, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM
NaCl, 2 mM EDTA) supplemented with protease and phospha-
tase inhibitor cocktail (Roche). Hindbrains were lysed in Tris
buffer (20mMTris at pH 9, 2% SDS) supplementedwith protease
and phosphatase inhibitor cocktail (Roche), boiled at 100°C, and
then incubated at 750 rpm at 80°C. Insoluble material was re-
moved, protein concentration was determined with the BCA pro-
tein assay kit (Thermo Scientific), and 10 μg of protein per lane
was separated by SDS-PAGE. DLL4 was detected using anti-
DLL4 (1:1000; Abcam, 7280) and membranes were reprobed
with anti-β-Actin antibody ( 1:100,000; Abcam, clone AC-15).
Band intensities ofDLL4 and β-Actinwere quantifiedwith Image-
Lab software (Bio-Rad).
Immunostaining
Hindbrains and retinaswere processed as described (del Toro et al.
2010; Pitulescu et al. 2010; Fantin et al. 2013), and tumors and
E10 embryoswere fixed in 4%PFA for 1 h on ice. After incubation
in blocking solution (10% normal donkey serum, 0.1% [v/v] Tri-
ton X-100 in PBS), samples were incubated overnight at 4°C with
the designated primary antibodies (MEF2A [Abcam], MEF2B
[Abcam], MEF2C [Cell Signaling], MEF2D [BD], EP300 [Active
Motif], HDAC4 [GeneTex], DLL4 [R&D Systems] isolectin B4
[IB4] [Vector Laboratories], and Erg [Abcam]) in 0.1% PBS-T. Sam-
ples were washed in PBS-T and incubated for 3 h with suitable
species-specific Alexa fluor- or biotin-conjugated secondary anti-
bodies in 0.1% PBS-T. Total numbers of branch points and tip
cells and retinal outgrowth length were measured after IB4 stain-
ing using ImageJ software from pooled images of retinas from at
least two independent litters.
Cell culture and ChIP
HUVECS (pooled) (Lonza) were grown as described previously
(Strasser et al. 2010; Sacilotto et al. 2013). For VEGF stimulation,
cells were starved for 18 h in EBM-2 medium (Lonza) and then
Sacilotto et al.
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incubated for 1 h with EBM-2 supplemented with 25 ng/mL
VEGFA165 (Peprotech, Lonza). ChIP assays were performed as de-
scribed (Sacilotto et al. 2013) using antibodies against EP300 (Ac-
tive Motif, 61401), HDAC4 (Proteintech, 60105-1), HDAC7
(Epigentek, A4007-050), HDAC9 (BioOrbyt, orb214926), Mef2A
(Abcam, ab109420), Mef2C (Cell Signaling, 5030S), and Mef2D
(BD, 610774). RNA isolation, cDNA synthesis, RT–PCR, and
quantitative RT–PCR (qRT–PCR) were performed as described
previously (Nikitenko et al. 2013) using primer/probes from Ap-
plied Biosystems. Dharmacon siRNA targeting human MEF2A,
MEF2C,MEF2D,or thenegativecontrol sequencewerepurchased
from GE Healthcare. Stealth siRNA targeting mouse Mef2A,
Mef2C, and Mef2D were purchased from Life Technologies. See
the Supplemental Material for sequences and catalog numbers.
siRNAswere transfected into primaryHUVECs or bENDcells ex-
pressing GFP (pGIPz-GFP-Puro HUVECs) at a final concentration
of 100 nM using Oligofectamine (Life Technologies). MEF2A,
MEF2C, orMEF2D stable knockdownwas performed using lenti-
viral particles containing shRNAmir for MEF2A, MEF2C,
MEF2D, or nonsilencing target (Open Biosystems).
Bioinformatic analysis of MEF2-enriched binding sites
MEF2C and corresponding H3K27ac ChIP-seq datawere obtained
using publicly available ChIP-seq data (Maejima et al. 2014)
accessible at NCBI Gene Expression Omnibus database (Edgar
et al. 2002), accession numbers GSE32547, GSE32644,
GSE32693, and GSE41553. Raw reads were trimmed with Sickle,
and duplicate PCR reads were removed with rmdup. Reads were
then aligned to human genome build hg19 using Bowtie2, and
peaks were called with MACS2. For the enrichment analysis,
RefSeq genes were obtained fromUniversity of California at San-
ta Cruz, and antisense genes were removed. MEF2C peaks were
required to reside <500 base pairs from a H3K27ac peak. Fisher’s
exact was used to determine enrichment of MEF2C peaks in or
around genes up-regulated in tip cells.
HDAC inhibitor assays
HUVECS were starved for 16 h in EBM-2; treated with 400 nM
TSA, 10 µM BML-210 (Abcam), 10 µM MC-1568 (Sigma), or
DMSO (incubation times are in the figure legends); and stimulat-
ed with EBM-2 supplemented with 25 ng/mL VEGF-A for 1 h be-
fore harvesting for RNA extraction. Embryo culture in TSA was
as described previously (Rojas et al. 2005) with modifications:
Whole embryos (with their heads) were incubated for 17 h in ei-
ther 100 µM TSA or control DMSO. In utero intracerebral injec-
tions were as described previously (Garcia-Moreno et al. 2014):
Each E12 embryo was injected with ∼1 μL of 10 µM TSA or
DMSO control, dyed with fast green into the fourth ventricle,
left in utero for 24 h, and then harvested.
Gene expression analysis
RNA extraction was carried out using the RNAspin minikit (GE
Healthcare) following the manufacturer’s instructions from ei-
therHUVECs (directly lysed on the cell culture plate in R1 buffer)
or whole-lung extracts (homogenized in liquid nitrogen using a
pestle and mortar and subsequently lysed in R1 buffer). Total
RNA (0.5–1 µg) was then retrotranscribed using random primers
and SuperScript III (Life Technologies) as per the manufacturer’s
instructions, and the cDNAwas analyzed by qRT–PCR (StepOne
Plus, Life Technologies) using gene-specific TaqMan probes (Ap-
plied Biosystems).
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